Type 2 Diabetes - Pipeline Review, H1 2017

  • ID: 4284844
  • Report
  • 1100 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Boehringer Ingelheim GmbH
  • Evotec AG
  • Kadimastem Ltd
  • NovaTarg Therapeutics Inc
  • Shionogi & Co Ltd
  • MORE
Type 2 Diabetes - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 22 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Boehringer Ingelheim GmbH
  • Evotec AG
  • Kadimastem Ltd
  • NovaTarg Therapeutics Inc
  • Shionogi & Co Ltd
  • MORE
Introduction

Type 2 Diabetes - Overview

Type 2 Diabetes - Therapeutics Development

Type 2 Diabetes - Therapeutics Assessment

Type 2 Diabetes - Companies Involved in Therapeutics Development

Type 2 Diabetes - Drug Profiles

Type 2 Diabetes - Dormant Projects

Type 2 Diabetes - Discontinued Products

Type 2 Diabetes - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Type 2 Diabetes, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Companies, H1 2017 (Contd..25), H1 2017

Products under Development by Companies, H1 2017 (Contd..26), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Type 2 Diabetes - Pipeline by 4P Therapeutics LLC, H1 2017

Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H1 2017

Type 2 Diabetes - Pipeline by Adocia, H1 2017

Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H1 2017

Type 2 Diabetes - Pipeline by Aegis Therapeutics LLC, H1 2017

Type 2 Diabetes - Pipeline by AFFiRiS AG, H1 2017

Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2017

Type 2 Diabetes - Pipeline by Allergan Plc, H1 2017

Type 2 Diabetes - Pipeline by Alteogen Inc, H1 2017

Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Type 2 Diabetes - Pipeline by Amgen Inc, H1 2017

Type 2 Diabetes - Pipeline by Anchor Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by AntriaBio Inc, H1 2017

Type 2 Diabetes - Pipeline by Aphios Corp, H1 2017

Type 2 Diabetes - Pipeline by Araim Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by ArisGen SA, H1 2017

Type 2 Diabetes - Pipeline by Astellas Pharma Inc, H1 2017

Type 2 Diabetes - Pipeline by AstraZeneca Plc, H1 2017

Type 2 Diabetes - Pipeline by AusBio Ltd, H1 2017

Type 2 Diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2017

Type 2 Diabetes - Pipeline by Bayer AG, H1 2017

Type 2 Diabetes - Pipeline by Beta-Cell NV, H1 2017

Type 2 Diabetes - Pipeline by Betagenon AB, H1 2017

Type 2 Diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Biocon Ltd, H1 2017

Type 2 Diabetes - Pipeline by BioLingus AG, H1 2017

Type 2 Diabetes - Pipeline by BioRestorative Therapies Inc, H1 2017

Type 2 Diabetes - Pipeline by Biozeus, H1 2017

Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2017

Type 2 Diabetes - Pipeline by Boston Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2017

Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2017

Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2017

Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017

Type 2 Diabetes - Pipeline by Cardax Inc, H1 2017

Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Celon Pharma SA, H1 2017

Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2017

Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Type 2 Diabetes - Pipeline by CJ HealthCare Corp, H1 2017

Type 2 Diabetes - Pipeline by CohBar Inc, H1 2017

Type 2 Diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017

Type 2 Diabetes - Pipeline by ConjuChem LLC, H1 2017

Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017

Type 2 Diabetes - Pipeline by ConSynance Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Corium International Inc, H1 2017

Type 2 Diabetes - Pipeline by CSL Ltd, H1 2017

Type 2 Diabetes - Pipeline by CureDM Inc, H1 2017

Type 2 Diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Type 2 Diabetes - Pipeline by Dance Biopharm Inc, H1 2017

Type 2 Diabetes - Pipeline by Delpor Inc, H1 2017

Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H1 2017

Type 2 Diabetes - Pipeline by DiaMedica Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Diamyd Medical AB, H1 2017

Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by DiscoveryBiomed Inc, H1 2017

Type 2 Diabetes - Pipeline by DNJ Pharma Inc, H1 2017

Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2017

Type 2 Diabetes - Pipeline by Enteris BioPharma Inc, H1 2017

Type 2 Diabetes - Pipeline by Enzo Biochem Inc, H1 2017

Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H1 2017

Type 2 Diabetes - Pipeline by Esperion Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Eternygen GmbH, H1 2017

Type 2 Diabetes - Pipeline by Evotec AG, H1 2017

Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Type 2 Diabetes - Pipeline by Generex Biotechnology Corp, H1 2017

Type 2 Diabetes - Pipeline by Genexine Inc, H1 2017

Type 2 Diabetes - Pipeline by Genfit SA, H1 2017

Type 2 Diabetes - Pipeline by Genmedica Therapeutics SL, H1 2017

Type 2 Diabetes - Pipeline by Genovate Biotechnology Co LTD, H1 2017

Type 2 Diabetes - Pipeline by Geropharm LLC, H1 2017

Type 2 Diabetes - Pipeline by Gilead Sciences Inc, H1 2017

Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H1 2017

Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017

Type 2 Diabetes - Pipeline by Glucox Biotech AB, H1 2017

Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H1 2017

Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017

Type 2 Diabetes - Pipeline by HanAll Biopharma Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd, H1 2017

Type 2 Diabetes - Pipeline by HitGen LTD, H1 2017

Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Immuron Ltd, H1 2017

Type 2 Diabetes - Pipeline by Innopharmax Inc, H1 2017

Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H1 2017

Type 2 Diabetes - Pipeline by Intarcia Therapeutics Inc, H1 2017

Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Type 2 Diabetes - Pipeline by Integral Molecular Inc, H1 2017

Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by Intrexon Corp, H1 2017

Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by Islet Sciences Inc, H1 2017

Type 2 Diabetes - Pipeline by Japan Tobacco Inc, H1 2017

Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Jenrin Discovery Inc, H1 2017

Type 2 Diabetes - Pipeline by JHL Biotech Inc, H1 2017

Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2017

Type 2 Diabetes - Pipeline by Kadimastem Ltd, H1 2017

Type 2 Diabetes - Pipeline by Kadmon Corp LLC, H1 2017

Type 2 Diabetes - Pipeline by Kareus Therapeutics SA, H1 2017

Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H1 2017

Type 2 Diabetes - Pipeline by Leading BioSciences Inc, H1 2017

Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Type 2 Diabetes - Pipeline by LG Chem, Ltd., H1 2017

Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals Inc, H1 2017

List of Figures:

Number of Products under Development for Type 2 Diabetes, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4P Therapeutics LLC
  • Addex Therapeutics Ltd
  • Adocia
  • Advinus Therapeutics Ltd
  • Aegis Therapeutics LLC
  • AFFiRiS AG
  • Alize Pharma SAS
  • Allergan Plc
  • Alteogen Inc
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Anchor Therapeutics Inc
  • AntriaBio Inc
  • Aphios Corp
  • Araim Pharmaceuticals Inc
  • Arena Pharmaceuticals Inc
  • Arisaph Pharmaceuticals Inc
  • ArisGen SA
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • AusBio Ltd
  • Avadel Pharmaceuticals Plc
  • Bayer AG
  • Beta-Cell NV
  • Betagenon AB
  • Betta Pharmaceuticals Co Ltd
  • Biocon Ltd
  • BioLingus AG
  • BioRestorative Therapies Inc
  • Biozeus
  • Biscayne Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Boston Therapeutics Inc
  • Braasch Biotech LLC
  • Bristol-Myers Squibb Company
  • C4X Discovery Holdings PLC
  • Cadila Pharmaceuticals Ltd
  • Cardax Inc
  • Carmot Therapeutics Inc
  • Celon Pharma SA
  • Chipscreen Biosciences Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • CohBar Inc
  • Concenter BioPharma Silkim Ltd
  • ConjuChem LLC
  • Connexios Life Sciences Pvt Ltd
  • ConSynance Therapeutics Inc
  • Corium International Inc
  • CSL Ltd
  • CureDM Inc
  • CymaBay Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Company Ltd
  • Dance Biopharm Inc
  • Delpor Inc
  • Diabetology (Products) Ltd
  • DiaMedica Therapeutics Inc
  • Diamyd Medical AB
  • Diasome Pharmaceuticals Inc
  • DiscoveryBiomed Inc
  • DNJ Pharma Inc
  • Dong-A Socio Holdings Co Ltd
  • Elcelyx Therapeutics Inc
  • Eli Lilly and Company
  • Enteris BioPharma Inc
  • Enzo Biochem Inc
  • Epichem Pty Ltd
  • Esperion Therapeutics Inc
  • Eternygen GmbH
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Generex Biotechnology Corp
  • Genexine Inc
  • Genfit SA
  • Genmedica Therapeutics SL
  • Genovate Biotechnology Co LTD
  • Geropharm LLC
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glide Pharmaceutical Technologies Ltd
  • Glucox Biotech AB
  • GW Pharmaceuticals Plc
  • Hadasit Medical Research Services & Development Ltd
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Heptares Therapeutics Ltd
  • HitGen LTD
  • Hyundai Pharmaceutical Co Ltd
  • Immuron Ltd
  • Innopharmax Inc
  • Innovative Targeting Solutions Inc
  • Intarcia Therapeutics Inc
  • Intas Pharmaceuticals Ltd
  • Integral Molecular Inc
  • Intercept Pharmaceuticals Inc
  • Intrexon Corp
  • Ionis Pharmaceuticals Inc
  • Ironwood Pharmaceuticals Inc
  • Islet Sciences Inc
  • Japan Tobacco Inc
  • Jeil Pharmaceutical Co Ltd
  • Jenrin Discovery Inc
  • JHL Biotech Inc
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Kadimastem Ltd
  • Kadmon Corp LLC
  • Kareus Therapeutics SA
  • Kissei Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Leading BioSciences Inc
  • Lexicon Pharmaceuticals Inc
  • LG Chem, Ltd.
  • Ligand Pharmaceuticals Inc
  • LipimetiX Development Inc
  • Lonestar Heart Inc
  • Longevity Biotech Inc
  • Luye Pharma Group Ltd
  • Magnus Life Ltd
  • Medesis Pharma SA
  • Medestea Research & Production SpA
  • MedImmune LLC
  • Medlab Clinical Ltd
  • Melior Discovery Inc
  • Mellitech SAS
  • Merck & Co Inc
  • Mesoblast Ltd
  • Metabolic Solutions Development Company LLC
  • Metabolys SAS
  • Metacrine Inc
  • Mitsubishi Tanabe Pharma Corp
  • Moderna Therapeutics Inc
  • Naia Ltd
  • Neurimmune Holding AG
  • Neurocrine Biosciences Inc
  • NGM Biopharmaceuticals Inc
  • Nordic Bioscience A/S
  • Novapeutics LLC
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Novo Nordisk A/S
  • Noxxon Pharma AG
  • Omeros Corp
  • OPKO Biologics Ltd
  • OPKO Health Inc
  • Oramed Pharmaceuticals Inc
  • Paras Biopharmaceuticals Finland Oy
  • Peptron Inc
  • Pfizer Inc
  • PharmaCyte Biotech Inc
  • PharmaIN Corp
  • Pila Pharma AB
  • Poxel SA
  • Prometheon Pharma LLC
  • ProMetic Life Sciences Inc
  • Purzer Pharmaceutical Co Ltd
  • Reata Pharmaceuticals Inc
  • ReCyte Therapeutics Inc
  • reMYND NV
  • Renova Therapeutics Inc
  • Reset Therapeutics Inc
  • Saniona AB
  • Sanofi
  • Sanwa Kagaku Kenkyusho Co Ltd
  • SATT Conectus Alsace SAS
  • SBI Pharmaceuticals Co Ltd
  • Seres Therapeutics Inc
  • Serodus ASA
  • Serometrix LLC
  • Sevion Therapeutics Inc
  • Shenzhen HighTide Biopharmaceutical Ltd
  • Shionogi & Co Ltd
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Sirona Biochem Corp
  • SJT Molecular Research SL
  • SK Chemicals Co Ltd
  • Sprint Bioscience AB
  • Sumitomo Dainippon Pharma Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Company Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • Teijin Pharma Ltd
  • The Medicines Company
  • Theracos Inc
  • Thermalin Diabetes LLC
  • Toray Industries Inc
  • Torrent Pharmaceuticals Ltd
  • Transgene Biotek Ltd
  • TTY Biopharm Company Ltd
  • Uni-Bio Science Group Ltd
  • Valeant Pharmaceuticals International Inc
  • ViaCyte Inc
  • Vichem Chemie Research Ltd
  • Vicore Pharma AB
  • Viking Therapeutics Inc
  • Vivus Inc
  • vTv Therapeutics Inc
  • Vybion Inc
  • XBiotech Inc
  • Xenetic Biosciences Inc
  • XL-protein GmbH
  • XOMA Corp
  • XuanZhu Pharma Co Ltd
  • Yuhan Corp
  • Yungjin Pharm Co Ltd
  • Zafgen Inc
  • Zealand Pharma AS
  • Zensun (Shanghai) Sci & Tech Co Ltd
  • Zydus Cadila Healthcare Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll